华夏恒生生物科技ETF(QDII)(159892)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
371,906,104.48 |
-112,054,503.11 |
-99,213,284.59 |
-18,836,429.50 |
| 本期利润 |
1,791,682,935.73 |
-283,183,888.16 |
-778,063,486.28 |
-236,559,139.54 |
| 加权平均基金份额本期利润 |
0.24 |
-0.04 |
-0.13 |
-0.09 |
| 本期加权平均净值利润率(%) |
41.79 |
-9.29 |
-30.02 |
-16.10 |
| 本期基金份额净值增长率(%) |
51.45 |
-12.72 |
-26.87 |
-22.12 |
| 期末可供分配利润 |
-1,628,347,467.82 |
-4,526,497,419.54 |
-3,982,464,880.70 |
-2,335,632,891.63 |
| 期末可供分配基金份额利润 |
-0.27 |
-0.52 |
-0.60 |
-0.45 |
| 期末基金资产净值 |
4,304,918,554.18 |
4,163,768,602.46 |
2,670,801,141.30 |
2,841,633,130.37 |
| 期末基金份额净值 |
0.73 |
0.48 |
0.40 |
0.55 |
| 基金份额累计净值增长率(%) |
-27.44 |
-52.09 |
-59.86 |
-45.11 |
微信公众号
证券之星APP
基本资料
